HT-1080人纤维肉瘤细胞

价 格:¥1800

期 货:现货(冻存管发2支)

保藏中心:BTCC

资源编号:BTCC-1074

产地:中国

套 餐:

T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

详细资料说明书下载质检报告(COA)

Cell line nameHT-1080
SynonymsHt-1080; HT 1080; HT1080; HT 1080.T
AccessionBTCC-1074
Resource Identification InitiativeTo cite this cell line use: HT-1080 (BTCC-1074)
CommentsPart of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Population: Caucasian.
Doubling time: 26 hours (PubMed=4132053); ~30 hours (DSMZ=ACC-315).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Misspelling: HT1180; Note=Occasionally.
Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (ATCC).
  • Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (PubMed=26368816).
  • Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=12068308; ATCC; Cosmic-CLP; DepMap).
HLA typingSource: PubMed=26589293
Class I
HLA-AA*31:01,68:01
HLA-BB*27:05,27:05
HLA-CC*02:02,02:02

Source: CLS=300216
Class I
HLA-AA*31:01:02,68:01:01
HLA-BB*27:05:02
HLA-CC*02:02:02
Class II
HLA-DPDPB1*03:01,04:01
HLA-DQDQA1*03:03:01,05:01:01

DQB1*02:01:01,03:01:01
HLA-DRDRB1*03:01:01,04:07:01

Source: DSMZCellDive=ACC-315
Class I
HLA-AA*31:01:02,68:01:01
HLA-BB*27:05:02,27:05:02
HLA-CC*02:02:02,02:02:02
Class II
HLA-DPDPA1*01:03:01,01:03:01

DPB1*04:01:01,04:01:01
HLA-DRDRA*01:01:01,01:02:02
Genome ancestrySource: PubMed=30894373

Origin% genome


African0.86
Native American0.35
East Asian, North1.36
East Asian, South0.29
South Asian0
European, North68.21
European, South28.94
DiseaseFibrosarcoma (NCIt: C3043)
Fibrosarcoma (ORDO: Orphanet_2030)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
HierarchyChildren:



CVCL_1D50 (2C4 [Human fibrosarcoma])CVCL_0115 (2fTGH)CVCL_8870 (FLYA13)
CVCL_8871 (FLYRD18)CVCL_RW47 (HL116)CVCL_3715 (HP)
CVCL_XG90 (HT-1080 JH-1/FIX)CVCL_DF43 (HT-1080 NucLight Green)CVCL_DF44 (HT-1080 NucLight Red)
CVCL_V355 (HT-1080 Tet-Off)CVCL_UZ99 (HT-1080-Luc2)CVCL_VI98 (HT-1080/Arabidopsis hybrid chr15)
CVCL_JG56 (HT-1080/CMV-Luc)CVCL_C3V7 (HT-1080/hCLDN-1)CVCL_C3V8 (HT-1080/hCLDN-2)
CVCL_C3V9 (HT-1080/hCLDN-3)CVCL_C3VA (HT-1080/hCLDN-4)CVCL_C3VB (HT-1080/hCLDN-5)
CVCL_C3VC (HT-1080/hCLDN-6)CVCL_C3VD (HT-1080/hCLDN-7)CVCL_C3VE (HT-1080/hCLDN-9)
CVCL_AR54 (HT-STAR)CVCL_C0RF (HT1080 EGFP)CVCL_C0RG (HT1080 EWSR1-FLI1-EGFP)
CVCL_AX37 (HT1080 FUS-DDIT3-EGFP)CVCL_XZ54 (HT1080 human CD137)CVCL_XZ55 (HT1080 human CD27)
CVCL_XZ56 (HT1080 human CD40)CVCL_UE32 (HT1080 human GITR)CVCL_UE31 (HT1080 human OX40)
CVCL_RA09 (HT1080-eGFP-Puro)CVCL_RA10 (HT1080-Fluc-Neo/eGFP-Puro)CVCL_RA11 (HT1080-Fluc-Neo/iRFP-Puro)
CVCL_RA12 (HT1080-Fluc-Puro)CVCL_RA13 (HT1080-hNIS-Neo/eGFP-Puro)CVCL_RA14 (HT1080-hNIS-Neo/Fluc-Puro)
CVCL_RA15 (HT1080-hNIS-Neo/iRFP-Puro)CVCL_RA16 (HT1080-hNIS-Puro)CVCL_RA17 (HT1080-iRFP-Puro)
CVCL_L898 (HT1080-luc2)CVCL_ZJ81 (HT1080-MFAP4 W235F-MH)CVCL_ZJ80 (HT1080-MFAP4 wt-MH)
CVCL_5I99 (HT1080-Red-FLuc)CVCL_6C48 (HT1080/DR4)CVCL_WM79 (HTC75)
CVCL_D683 (HTD114)CVCL_3318 (HX)CVCL_V634 (JH-2/TPA)
CVCL_8437 (PEAZ-1)

Sex of cellMale
Age at sampling35Y
CategoryCancer cell line
STR profileSource(s): ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; CelloPub=CLPUB00698; PubMed=11416159; PubMed=17254797; PubMed=25877200; RCB

Markers:
AmelogeninX,Y
CSF1PO11 (PubMed=17254797)
12 (ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; PubMed=25877200; RCB)
D2S133825,26
D3S135816
D5S81811,13
D7S8209,10
D8S117913,14
D13S31712,14
D16S5399,12
D18S5112,18
D19S43313.2,15 (CCRID)
14,15 (DSMZ)
D21S1128,30
FGA22,25
Penta D9,12
Penta E5,15
TH016
TPOX8
vWA14,19

Run an STR similarity search on this cell line
Web pageshttps://en.wikipedia.org/wiki/HT1080
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-124.html
https://tcpaportal.org/mclp/
Publications

PubMed=4132053; DOI=10.1002/1097-0142(197404)33:4<1027::aid-cncr2820330419>3.0.CO;2-Z
Rasheed S., Nelson-Rees W.A., Toth E.M., Arnstein P., Gardner M.B.
Characterization of a newly derived human sarcoma cell line (HT-1080).
Cancer 33:1027-1033(1974)

PubMed=375235; DOI=10.1073/pnas.76.3.1288
Sherwin S.A., Sliski A.H., Todaro G.J.
Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces.
Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979)

PubMed=22282976; DOI=10.1093/carcin/1.1.21
Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.
Human tumor cell strains defective in the repair of alkylation damage.
Carcinogenesis 1:21-32(1980)

PubMed=6652615; DOI=10.1016/0165-4608(83)90092-4
Chen T.-R., Hay R.J., Macy M.L.
Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins.
Cancer Genet. Cytogenet. 10:351-362(1983)

PubMed=6538202; DOI=10.1083/jcb.98.3.1133
Azzarone B., Suarez H., Mingari M.C., Moretta L., Fauci A.S.
4F2 monoclonal antibody recognizes a surface antigen on spread human fibroblasts of embryonic but not of adult origin.
J. Cell Biol. 98:1133-1137(1984)

PubMed=3986962; DOI=10.1093/carcin/6.4.549
Watatani M., Ikenaga M., Hatanaka T., Kinuta M., Takai S.-I., Mori T., Kondo S.
Analysis of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced DNA damage in tumor cell strains from Japanese patients and demonstration of MNNG hypersensitivity of Mer xenografts in athymic nude mice.
Carcinogenesis 6:549-553(1985)

PubMed=3558490; DOI=10.1002/jcp.1041300303
Gupta R.S., Dudani A.K.
Species-specific differences in the toxicity of rhodamine 123 towards cultured mammalian cells.
J. Cell. Physiol. 130:321-327(1987)

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=3413074; DOI=10.1073/pnas.85.16.6042
Pereira-Smith O.M., Smith J.R.
Genetic analysis of indefinite division in human cells: identification of four complementation groups.
Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988)

PubMed=11668190; DOI=10.1177/002215540104901105
Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.
Immunocytochemical analysis of cell lines derived from solid tumors.
J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

CLPUB00698
van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Tehrani M.J., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24726063; DOI=10.1186/1756-9966-33-33
Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B., Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R., Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=26368816; DOI=10.1371/journal.pone.0133813
Li L., Paz A.C., Wilky B.A., Johnson B., Galoian K., Rosenberg A., Hu G., Tinoco G., Bodamer O.A., Trent J.C.
Treatment with a small molecule mutant IDH1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in human chondrosarcoma cells.
PLoS ONE 10:E0133813-E0133813(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line databases/resourcesCLO; CLO_0004266
CLO; CLO_0004276
MCCL; MCC:0000210
CLDB; cl1735
CLDB; cl1736
CLDB; cl1737
CLDB; cl1738
CLDB; cl1740
CLDB; cl1741
CLDB; cl1742
CLDB; cl4913
CCRID; 1101HUM-PUMC000070
CCRID; 3101HUMTCHu170
CCRID; 4201HUM-CCTCC00105
Cell_Model_Passport; SIDM00828
Cosmic-CLP; 907064
DepMap; ACH-000054
DSMZCellDive; ACC-315
IGRhCellID; HT1080
LINCS_LDP; LCL-1435
Lonza; 744
TOKU-E; 1963
Anatomy/cell type resourcesBTO; BTO:0001282
Biological sample resourcesBioSample; SAMN01821563
BioSample; SAMN01821634
BioSample; SAMN01821685
BioSample; SAMN01821731
BioSample; SAMN03471913
BioSample; SAMN10987635
ENCODE; ENCBS039VHD
ENCODE; ENCBS225AAA
ENCODE; ENCBS512AAA
ENCODE; ENCBS513AAA
ENCODE; ENCBS617SGR
ENCODE; ENCBS688VJF
ENCODE; ENCBS798NML
ENCODE; ENCBS816VMN
ENCODE; ENCBS937RAY
Cell line collections (Providers)ATCC; CCL-121
ATCC; CRL-7951 - Discontinued
BCRC; 60037
BCRJ; 0110
CCTCC; GDC0105
CLS; 300216
DSMZ; ACC-315
ECACC; 85111505
IBRC; C10104
ICLC; HTL98016
IZSLER; BS TCL 27
JCRB; IFO50354
JCRB; JCRB9113
KCB; KCB 2013029YJ
KCLB; 10121
NCBI_Iran; C437
RCB; RCB1956 - Discontinued
TKG; TKG 0202
Chemistry resourcesChEMBL-Cells; CHEMBL3308396
ChEMBL-Targets; CHEMBL614580
GDSC; 907064
PharmacoDB; HT1080_625_2019
PubChem_Cell_line; CVCL_0317
Encyclopedic resourcesWikidata; Q5636047
Experimental variables resourcesEFO; EFO_0002059

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部